The FDA is reviewing a possible link between the asthma drug Xolair and an increased risk of heart and cerebrovascular disorders.

Since the FDA investigation is still under way, the agency is not telling doctors to stop prescribing Xolair and is not recommending any changes to the prescribing information for Xolair.

More...